NAD+ Peptide Complex
Also known as: NAD+, Nicotinamide Adenine Dinucleotide
Overview
While NAD+ (nicotinamide adenine dinucleotide) is technically a coenzyme rather than a peptide, it is a central component of peptide therapy protocols targeting mitochondrial function and aging. NAD+ levels decline 50%+ with aging, contributing to mitochondrial dysfunction, reduced DNA repair, and epigenetic aging. IV NAD+ therapy and oral NAD+ precursors (NMN, NR) are widely used alongside mitochondrial peptides (SS-31, MOTS-c) and NNMT inhibitors (5-Amino-1MQ) in comprehensive anti-aging protocols.
Mechanism of Action
NAD+ serves as a cofactor for: sirtuins (SIRT1-7) regulating gene expression, DNA repair, and metabolism; poly(ADP-ribose) polymerases (PARPs) for DNA damage repair; CD38/CD157 ectoenzymes regulating calcium signaling; and the electron transport chain for ATP synthesis. Restoration of NAD+ reactivates these pathways. When combined with NNMT inhibitors like 5-Amino-1MQ, the combination addresses both supply (NAD+ therapy) and conservation (NNMT inhibition) for sustained cellular effects.
Potential Benefits
- Restoration of mitochondrial electron transport chain efficiency
- Reactivation of SIRT1-7 longevity pathways
- Enhanced DNA repair capacity via PARP reactivation
- Improved cellular energy metabolism
- Synergistic with MOTS-c, SS-31, and 5-Amino-1MQ in anti-aging stacks
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 250-1000 mg/day oral precursors; 100-1000 mg IV NAD+ |
| Beginner | 250-500 mg NMN or NR orally daily |
| Intermediate | 500-1000 mg NMN daily; or 250-500 mg IV weekly |
| Advanced | 1000 mg IV NAD+ 1-3x/week; high-dose NMN/NR orally |
| Cycle Duration | Continuous oral; IV typically 4-8 week courses |
| Cycle Off | IV courses: 4-8 weeks off; oral precursors may be continued indefinitely |
IV NAD+ provides the most direct cellular repletion. IV administration often causes mild flushing, chest tightness, or nausea during infusion — slow administration rate resolves this. NAD+ levels naturally decline ~50% by age 50.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High — systemic distribution
Most common administration route for research peptides. Inject into abdominal fat, thigh, or upper arm. Rotate sites. standard research dose.
Intramuscular Injection High — with slightly faster onset than SC
Alternative route when deeper delivery or faster absorption is desired. Less commonly used than SC for most research peptides.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving NAD+ Peptide Complex:
Longevity Stack
NAD+ Peptide Complex combined with telomere-supporting Epithalon and NAD+ precursors for broad longevity protocol. Cycled over 10-20 day blocks.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 500mg/50ml IV solution, 100mg injectable vials, 250mg/500mg oral capsules |
|---|---|
| BAC Water | IV solutions in saline; injectable vials use sterile water |
| Storage | Refrigerate IV/injectable formulations at 2-8°C; oral capsules at room temperature |
| Shelf Life | 24 months sealed; follow manufacturer guidance for opened formulations |
Need exact syringe measurements?
Amino Acid Sequence
N/A (coenzyme, not a peptide)
Side Effects & Safety
- IV NAD+: flushing, nausea, chest tightness during infusion (temporary)
- Oral precursors: generally well-tolerated
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | NAD+ precursors vary; intracellular NAD+ levels rise for hours-days after dosing |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside NAD+ Peptide Complex for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.